Cecchi, F.; Rex, K.; Schmidt, J.; Vocke, C.D.; Lee, Y.H.; Burkett, S.; Baker, D.; Damore, M.A.; Coxon, A.; Burgess, T.L.;
et al. Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Cancers 2023, 15, 460.
https://doi.org/10.3390/cancers15020460
AMA Style
Cecchi F, Rex K, Schmidt J, Vocke CD, Lee YH, Burkett S, Baker D, Damore MA, Coxon A, Burgess TL,
et al. Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Cancers. 2023; 15(2):460.
https://doi.org/10.3390/cancers15020460
Chicago/Turabian Style
Cecchi, Fabiola, Karen Rex, Joanna Schmidt, Cathy D. Vocke, Young H. Lee, Sandra Burkett, Daniel Baker, Michael A. Damore, Angela Coxon, Teresa L. Burgess,
and et al. 2023. "Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling" Cancers 15, no. 2: 460.
https://doi.org/10.3390/cancers15020460
APA Style
Cecchi, F., Rex, K., Schmidt, J., Vocke, C. D., Lee, Y. H., Burkett, S., Baker, D., Damore, M. A., Coxon, A., Burgess, T. L., & Bottaro, D. P.
(2023). Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Cancers, 15(2), 460.
https://doi.org/10.3390/cancers15020460